Cargando…
Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
BACKGROUND: Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results from several completed clinical trials are mixed and contradictory. Proper interpretations of these clinical observations,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035024/ https://www.ncbi.nlm.nih.gov/pubmed/21247479 http://dx.doi.org/10.1186/1750-1326-6-7 |